|
ID
|
Year
|
Country
|
Sample size (high/low)
|
Cancer type
|
Method
|
Outcomes
|
HR availability
|
Follow-up months (mouth)
|
NOS Score
|
|---|
|
Zhu 2020 [35]
|
2020
|
China
|
60 (30/30)
|
Osteosarcoma
|
qRT-PCR
|
OS, PFS, CP
|
K-M curve
|
60
|
5
|
|
Lv 2019 [27]
|
2019
|
China
|
114 (58/56)
|
Cervical cancer
|
qRT-PCR
|
OS, PFS, CP
|
K-M curve
|
60
|
6
|
|
Wan 2016 [18]
|
2016
|
China
|
58 (27/31)
|
Lung cancer
|
qRT-PCR
|
OS, CP
|
K-M curve
|
60
|
6
|
|
Wang 2020 [28]
|
2020
|
China
|
67 (37/30)
|
Pancreatic ductal adenocarcinoma
|
qRT-PCR
|
OS, CP
|
K-M curve
|
60
|
6
|
|
Wu 2019 [26]
|
2019
|
China
|
73 (37/36)
|
Colorectal cancer
|
qRT-PCR
|
OS, CP
|
K-M curve
|
60
|
6
|
|
Wu 2020 [23]
|
2020
|
China
|
106 (70/36)
|
Osteosarcoma
|
qRT-PCR
|
OS, PFS, CP
|
K-M curve
|
60
|
6
|
|
Zhang 2020 [34]
|
2020
|
China
|
106 (53/53)
|
Bladder cancer
|
qRT-PCR
|
OS, PFS, CP
|
K-M curve
|
150
|
7
|
|
Xu 2018 [33]
|
2018
|
China
|
72 (36/36)
|
Gastric cancer
|
qRT-PCR
|
OS, CP
|
K-M curve
|
100
|
6
|
|
Shi 2018 [25]
|
2018
|
China
|
60 (31/29)
|
Lung cancer
|
qRT-PCR
|
CP
|
K-M curve
|
–
|
6
|
|
Kong 2019 [24]
|
2019
|
China
|
42 (18/24)
|
Ovarian cancer
|
qRT-PCR
|
CP
|
K-M curve
|
–
|
6
|
- OS overall survival, PFS progression-free survival, CP clinicopathological parameters, NOS Newcastle–Ottawa Scale, K-M curve Kaplan–Meier curve, qRT-PCR quantitative real time polymerase chain reaction, -, not available or invalid
